Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Di Pan

Showing results (151-160 of 153) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 153 results.
Journal of Medicinal Chemistry|July 6, 2023
Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer TreatmentSiyu He, Xianglin Chu, Yujia Wu, et al.
Acta Pharmacologica Sinica|May 9, 2025
Generating potent and persistent antitumor immunity via affinity-tuned CAR-T cells targeting mesothelinYa-Li Yue, Jun-Jun Liu, Hang Ma, et al.
Acta Pharmacologica Sinica|June 10, 2024
T cell-redirecting antibody for treatment of solid tumors via targeting mesothelinJun-Jun Liu, Zhi-di Pan, Ya-Li Yue, et al.
Pageof 16

Showing results (151-160 of 153) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 153 results.
Journal of Medicinal Chemistry|July 6, 2023
Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer TreatmentSiyu He, Xianglin Chu, Yujia Wu, et al.
Acta Pharmacologica Sinica|May 9, 2025
Generating potent and persistent antitumor immunity via affinity-tuned CAR-T cells targeting mesothelinYa-Li Yue, Jun-Jun Liu, Hang Ma, et al.
Acta Pharmacologica Sinica|June 10, 2024
T cell-redirecting antibody for treatment of solid tumors via targeting mesothelinJun-Jun Liu, Zhi-di Pan, Ya-Li Yue, et al.
Pageof 16